|Filed Under:||Medical / Pharmaceutical|
|Posts on Regator:||3469|
|Posts / Week:||10.3|
|Archived Since:||November 10, 2008|
A new study claims marketing exclusivity for a drug maker caused higher patient costs.
Global spending on oncology treatments reached $100 billion last year, which represented a 10.3% increase from the previous year and a substantial rise from $75 billion spent five years ago, a new report says.
Good morning, everyone, and how are you today? A bright and shiny sun is enveloping the Pharmalot campus, where the official mascots are fertilizing the newly manicured grounds and the shortest of short people has left for the local schoolhouse. Show More Summary
Merck KGgA, the German drug maker, is concerned about ongoing confusion over the Merck name, which is shared by the U.S. drug maker.
A generic version of Vicodin, a powerful prescription painkiller, was the most widely prescribed drug to Medicare beneficiaries in 2013.
Good morning, everyone, and welcome to another working week. Another weekend respite has flown by, although we hope it was invigorating because, as you know, the routine of meetings and deadlines and what not has now returned. This means...Show More Summary
An Express Scripts unit has agreed to pay $60 million to resolve allegations by U.S. authorities that it participated in a kickback scheme with Novartis that caused federal health care programs to pay for a medicine based on false claims, according to court documents.
Tucked into a Congressional draft bill called 21st Century Cures for jump starting medical innovation is a passage that would undo a portion of a federal law requiring drug and device makers to disclose payments to physicians.
The pharmaceutical is on edge as more local governments adopt take-back programs that require drug makers pay the costs.
The latest comings and goings in the pharmaceutical industry.
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We hope to fire up the retooled lawncutter, spend time with assorted short people and catch up on our reading, when we are not napping. Show More Summary
TheAlabama legislature passed a bill that shields brand-name drug makers from lawsuits filed by consumers who claim they were harmed by generic versions and Gov. Robert Bentley has indicated he plans to sign the bill into law.
Good morning, everyone. How are you doing so far? Another busy day is upon us, although we are cheered by the presence of a warm and shiny sun enveloping the unusually quiet Pharmalot campus. The short people are scattered about. The official mascots are snoozing. Show More Summary
A vote on a closely watched California state bill that would force drug makers to disclose their costs was postponed yesterday, the second time this month the legislation failed to proceed after encountering opposition from the pharmaceutical industry.
Otsuka Pharmaceuticals was dealt a setback yesterday when the FDA approved four generic versions of its best-selling antipsychotic pill Abilify, following an unusual and protracted legal battle.
Australian regulators have approved a new code of conduct for the pharmaceutical industry that requires drug makers to disclose payments made to physicians for speaking and consulting, as well as travel.
Rise and shine, everyone, the middle of the week has arrived. This calls for a celebratory cup or two of stimulation. How so? Well, you made it this far, which can be an accomplishment, after all. Moreover, there is always good reason to forge ahead, given that there is so much more to do and the effort just might pay off. Show More Summary
In a big boost for Merck, the drug maker late yesterday disclosed positive news about a long-awaited clinical trial that was designed to test the safety of its best-selling Januvia diabetes tablet. Known as Tecos, the trial showed that Januvia met the primary goal of showing comparable cardiovascular safety versus a placebo. Show More Summary
A new report is encouraging the Centers for Medicare & Medicaid Services and Congress to pursue additional rebates for prescription drugs purchased for the Medicare Part D program.
Hello, everyone, and how are you today? A bright, shiny sun is enveloping the Pharmalot campus, where the short people have departed for assorted destinations and the official mascots are fertilizing the grounds. As for us, we are contemplating...Show More Summary